Cargando…
Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer
BACKGROUND: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and developed GI cancer differs from survival of first primary GI cancer patients. METHODS: Overall and cause‐specific survival...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346242/ https://www.ncbi.nlm.nih.gov/pubmed/30592184 http://dx.doi.org/10.1002/cam4.1922 |
_version_ | 1783389725706420224 |
---|---|
author | Rigter, Lisanne S. Schaapveld, Michael Janus, Cecile P. M. Krol, Augustinus D. G. van der Maazen, Richard W. M. Roesink, Judith Zijlstra, Josee M. van Imhoff, Gustaaf W. Poortmans, Philip M. P. Beijert, Max Lugtenburg, Pieternella J. Visser, Otto Snaebjornsson, Petur van Eggermond, Anna M. Aleman, Berthe M. P. van Leeuwen, Flora E. van Leerdam, Monique E. |
author_facet | Rigter, Lisanne S. Schaapveld, Michael Janus, Cecile P. M. Krol, Augustinus D. G. van der Maazen, Richard W. M. Roesink, Judith Zijlstra, Josee M. van Imhoff, Gustaaf W. Poortmans, Philip M. P. Beijert, Max Lugtenburg, Pieternella J. Visser, Otto Snaebjornsson, Petur van Eggermond, Anna M. Aleman, Berthe M. P. van Leeuwen, Flora E. van Leerdam, Monique E. |
author_sort | Rigter, Lisanne S. |
collection | PubMed |
description | BACKGROUND: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and developed GI cancer differs from survival of first primary GI cancer patients. METHODS: Overall and cause‐specific survival of GI cancer patients in a HL survivor cohort (GI‐HL, N = 104, including esophageal, gastric, small intestinal, and colorectal cancer) was compared with survival of a first primary GI cancer patient cohort (GI‐1, N = 1025, generated by case matching based on tumor site, gender, age, and year of diagnosis). Cox proportional hazards regression was used for survival analyses. Multivariable analyses were adjusted for GI cancer stage, grade of differentiation, surgery, radiotherapy, and chemotherapy. RESULTS: GI‐HL cancers were diagnosed at a median age of 54 years (interquartile range 45‐60). No differences in tumor stage or frequency of surgery were found. GI‐HL patients less often received radiotherapy (8% vs 23% in GI‐1 patients, P < 0.001) and chemotherapy (28% vs 41%, P = 0.01) for their GI tumor. Compared with GI‐1 patients, overall and disease‐specific survival of GI‐HL patients was worse (univariable hazard ratio (HR) 1.30, 95% confidence interval (CI) 1.03‐1.65, P = 0.03; and HR 1.29, 95% CI 1.00‐1.67, P = 0.049, respectively; multivariable HR 1.33, 95% CI 1.05‐1.68, P = 0.02; and HR 1.33, 95% CI 1.03‐1.72, P = 0.03, respectively). CONCLUSIONS: Long‐term overall and disease‐specific survival of GI cancer in HL survivors is worse compared with first primary GI cancer patients. Differences in tumor stage, grade of differentiation, or treatment could not explain this worse survival. |
format | Online Article Text |
id | pubmed-6346242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63462422019-01-29 Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer Rigter, Lisanne S. Schaapveld, Michael Janus, Cecile P. M. Krol, Augustinus D. G. van der Maazen, Richard W. M. Roesink, Judith Zijlstra, Josee M. van Imhoff, Gustaaf W. Poortmans, Philip M. P. Beijert, Max Lugtenburg, Pieternella J. Visser, Otto Snaebjornsson, Petur van Eggermond, Anna M. Aleman, Berthe M. P. van Leeuwen, Flora E. van Leerdam, Monique E. Cancer Med Clinical Cancer Research BACKGROUND: Hodgkin lymphoma (HL) survivors have an increased risk of gastrointestinal (GI) cancer. This study aims to evaluate whether survival of patients who survived HL and developed GI cancer differs from survival of first primary GI cancer patients. METHODS: Overall and cause‐specific survival of GI cancer patients in a HL survivor cohort (GI‐HL, N = 104, including esophageal, gastric, small intestinal, and colorectal cancer) was compared with survival of a first primary GI cancer patient cohort (GI‐1, N = 1025, generated by case matching based on tumor site, gender, age, and year of diagnosis). Cox proportional hazards regression was used for survival analyses. Multivariable analyses were adjusted for GI cancer stage, grade of differentiation, surgery, radiotherapy, and chemotherapy. RESULTS: GI‐HL cancers were diagnosed at a median age of 54 years (interquartile range 45‐60). No differences in tumor stage or frequency of surgery were found. GI‐HL patients less often received radiotherapy (8% vs 23% in GI‐1 patients, P < 0.001) and chemotherapy (28% vs 41%, P = 0.01) for their GI tumor. Compared with GI‐1 patients, overall and disease‐specific survival of GI‐HL patients was worse (univariable hazard ratio (HR) 1.30, 95% confidence interval (CI) 1.03‐1.65, P = 0.03; and HR 1.29, 95% CI 1.00‐1.67, P = 0.049, respectively; multivariable HR 1.33, 95% CI 1.05‐1.68, P = 0.02; and HR 1.33, 95% CI 1.03‐1.72, P = 0.03, respectively). CONCLUSIONS: Long‐term overall and disease‐specific survival of GI cancer in HL survivors is worse compared with first primary GI cancer patients. Differences in tumor stage, grade of differentiation, or treatment could not explain this worse survival. John Wiley and Sons Inc. 2018-12-27 /pmc/articles/PMC6346242/ /pubmed/30592184 http://dx.doi.org/10.1002/cam4.1922 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Rigter, Lisanne S. Schaapveld, Michael Janus, Cecile P. M. Krol, Augustinus D. G. van der Maazen, Richard W. M. Roesink, Judith Zijlstra, Josee M. van Imhoff, Gustaaf W. Poortmans, Philip M. P. Beijert, Max Lugtenburg, Pieternella J. Visser, Otto Snaebjornsson, Petur van Eggermond, Anna M. Aleman, Berthe M. P. van Leeuwen, Flora E. van Leerdam, Monique E. Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer |
title | Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer |
title_full | Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer |
title_fullStr | Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer |
title_full_unstemmed | Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer |
title_short | Overall and disease‐specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer |
title_sort | overall and disease‐specific survival of hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346242/ https://www.ncbi.nlm.nih.gov/pubmed/30592184 http://dx.doi.org/10.1002/cam4.1922 |
work_keys_str_mv | AT rigterlisannes overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT schaapveldmichael overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT januscecilepm overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT krolaugustinusdg overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT vandermaazenrichardwm overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT roesinkjudith overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT zijlstrajoseem overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT vanimhoffgustaafw overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT poortmansphilipmp overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT beijertmax overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT lugtenburgpieternellaj overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT visserotto overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT snaebjornssonpetur overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT vaneggermondannam overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT alemanberthemp overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT vanleeuwenflorae overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer AT vanleerdammoniquee overallanddiseasespecificsurvivalofhodgkinlymphomasurvivorswhosubsequentlydevelopedgastrointestinalcancer |